Evgen Pharma (LON:EVG) posted its quarterly earnings results on Tuesday. The company reported GBX (1.43) (($0.02)) earnings per share for the quarter, Digital Look Earnings reports.
EVG stock remained flat at $GBX 7.75 ($0.10) during trading hours on Tuesday. 78,033 shares of the company’s stock were exchanged, compared to its average volume of 207,445. The company has a market capitalization of $9.97 million and a PE ratio of -2.87. The company’s fifty day moving average is GBX 10.19 and its 200-day moving average is GBX 15.34. Evgen Pharma has a 12-month low of GBX 5.50 ($0.07) and a 12-month high of GBX 33 ($0.43).
Separately, FinnCap reissued a “corporate” rating on shares of Evgen Pharma in a research note on Tuesday.
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.
Recommended Story: What is the quiet period?
Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.